English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The prognosis of relapsed Ewing sarcoma family of tumor (ESFT) continues to be miserable. In such cases, the purpose of treatment should be palliative care. We report a case of a boy with relapsed EFST who was treated with irinotecan hydrochloride. This treatment was able to provide him with a transient improvement of quality of life. Irinotecan was administered at a dose of 40 mg/m2/day for three consecutive days. Thereafter, it was stopped for four days and was subsequently administered for an additional three days. This course was repeated in 21–28 days cycles. We were able to observe an improvement of images using technetium-99m-bone scans. We did not observe any signs of new tumor lesions for up to five months. The pain was relieved and no serious adverse effects were observed. While the efficacy of irinotecan remains to be confirmed, in many cases, irinotecan can be effective for relapsed ESFT.

Transient Improvement of the Quality-of-Life after Irinotecan Hydrochloride Therapy in a Child with Relapsed Ewing Sarcoma Family of Tumor